Financial Results For The Quarter Ended December 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.1 pts more than Nifty Microcap 250 and 9.5 pts more than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Globalspace Technologies reported Q3 FY26 standalone revenue of Rs 1,256.85 lakhs, up about 38.5% from Rs 907.51 lakhs in Q3 FY25, with a sequential jump from Rs 518.33 lakhs in Q2 FY26. Standalone net profit came in at Rs 46.27 lakhs versus Rs 61.90 lakhs a year ago, while nine-month FY26 PAT swung to a profit of Rs 76.18 lakhs from a loss of Rs 192.44 lakhs in the same period last year. On a consolidated basis, Q3 revenue grew to Rs 1,663.50 lakhs (vs Rs 1,268.98 lakhs) and nine-month PAT improved to Rs 40.18 lakhs from a loss of Rs 184.43 lakhs. The Board also approved a corporate guarantee of Rs 98 lakhs for subsidiary Innopharm Healthcare's overdraft facility from Axis Bank. The auditor issued an unqualified review opinion but flagged that the inventory register is not properly updated, statutory payments were delayed, and subsidiary financials were not independently reviewed.
Strong topline growth and a turnaround to profitability on a nine-month basis are positives for shareholders, though quarterly standalone PAT dipped YoY. The corporate guarantee exposes the company to potential liability if its subsidiary defaults, warranting close monitoring.